Through the partnership, IBM is harnessing supercomputer IBM Watson‘s technology to help providers combine and analyze genomic sequencing data with medical literature and pharmaceutical information to find the best treatment paths for individual cancer patients, according to an NPR report. Watson’s core capability, which helped it win on Jeopardy!, is the ability to quickly process massive amounts of information and come to a conclusion.
With the help of Watson, Robert Darnell, MD, PhD, founding director of the New York Genome Center and a neuro-oncologist at Rockefeller University, and his group studied 30 patients with glioblastoma, an aggressive form of brain cancer, and developed personalized treatment options for each patient “based on genetic mutations present in the tumor,” Dr. Darnell said, according to NPR. Dr. Darnell did not disclose specifics of the findings, as they have not yet been published. But, he told NPR, “there are patients who will benefit” from this study.
Now IBM and the New York Genome Center are looking to find out whether Watson can apply what he learned from Dr. Darnell’s research to a larger group of glioblastoma patients, according to NPR.
Dr. Darnell told NPR he wants to ultimately execute a large-scale clinical trial, recruiting “any cancer patient who is sick, not necessarily from glioblastoma.”
More articles on health IT:
Banner Health cyberattack brings layered security strategy into focus
Company issuing health plan ID cards hit with data breach affecting 3.3M
Physician files class-action lawsuit against Banner over data breach
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
